Analytical Data
-
Gene name
SAA1
- Application
-
Alternative Names
SAA1；Serum amyloid A-1 Protein
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P0DJI8
-
Expression Region
19-122aa
-
AA Sequence
RSFFSFLGEA FDGARDMWRA YSDMREANYI GSDKYFHARG NYDAAKRGPG GVWAAEAISD ARENIQRFFG HGAEDSLADQ AANEWGRSGK DPNHFRPAGL PEKY
-
Molecular Weight
11.7 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The SAA1 (Serum Amyloid A1) protein is a significant acute-phase reactant, primarily produced by the liver in response to inflammation. Its levels can increase dramatically during inflammatory conditions, making it a potential biomarker for various diseases, including autoimmune disorders, infections, and chronic inflammatory states. Research into SAA1 has gained prominence due to its role in the pathogenesis of amyloidosis, a condition characterized by the deposition of amyloid proteins in tissues and organs, leading to dysfunction. The recombinant production of SAA1 protein is crucial for elucidating its structural and functional properties, as well as for developing targeted therapeutic interventions. By using recombinant DNA technology, researchers can produce large quantities of SAA1 protein, facilitating studies on its interactions with other molecules, its regulatory mechanisms in inflammation, and its potential role in the immune response. These investigations may contribute to a better understanding of how SAA1 influences disease processes and its potential as a therapeutic target or diagnostic marker in clinical settings. Overall, ongoing research involving SAA1 recombinant protein aims to bridge the gap between molecular biology and clinical application, ultimately enhancing our understanding of disease mechanisms and improving patient outcomes.
